MicroRNA binding site polymorphisms as biomarkers of cancer risk

References

• Chen K, Song F, Calin GA, Wei Q, Hao X, Zhang W. Polymorphisms in microRNA targets: a gold mine for molecular epidemiology. Carcinogenesis29(7), 1306–1311 (2008).
   PubMed Web of Science ®Google Scholar
• Medina PP, Slack FJ. MicroRNAs and cancer: an overview. Cell Cycle7(16), 2485–2492 (2008).
   PubMed Web of Science ®Google Scholar
• Chang TC, Mendell JT. MicroRNAs in vertebrate physiology and human disease. Annu. Rev. Genomics. Hum. Genet.8, 215–239 (2007).
   PubMed Web of Science ®Google Scholar
• Sheng Y, Engstrom PG, Lenhard B. Mammalian microRNA prediction through a support vector machine model of sequence and structure. PloS ONE2(9), e946 (2007).
   PubMed Web of Science ®Google Scholar
• Griffiths-Jones S. miRBase: the microRNA sequence database. Methods Mol. Biol.342, 129–138 (2006).
   PubMedGoogle Scholar
• Alvarez-Garcia I, Miska EA. MicroRNA functions in animal development and human disease. Development132(21), 4653–4662 (2005).
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell116(2), 281–297 (2004).
   PubMed Web of Science ®Google Scholar
• Iorio MV, Croce CM. MicroRNAs in cancer: small molecules with a huge impact. J. Clin. Oncol.27(34), 5848–5856 (2009).
   PubMed Web of Science ®Google Scholar
• Khvorova A, Reynolds A, Jayasena SD. Functional siRNAs and miRNAs exhibit strand bias. Cell115(2), 209–216 (2003).
   PubMed Web of Science ®Google Scholar
• Schwarz DS, Hutvagner G, Du T, Xu Z, Aronin N, Zamore PD. Asymmetry in the assembly of the RNAi enzyme complex. Cell115(2), 199–208 (2003).
   PubMed Web of Science ®Google Scholar
• Doench JG, Sharp PA. Specificity of microRNA target selection in translational repression. Genes Dev.18(5), 504–511 (2004).
   PubMed Web of Science ®Google Scholar
• Vella MC, Choi EY, Lin SY, Reinert K, Slack FJ. The C. elegans microRNA let-7 binds to imperfect let-7 complementary sites from the lin-41 3´UTR. Genes Dev.18(2), 132–137 (2004).
   PubMed Web of Science ®Google Scholar
• Brennecke J, Stark A, Russell RB, Cohen SM. Principles of microRNA-target recognition. PLoS Biol.3(3), e85 (2005).
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell136(2), 215–233 (2009).
   PubMed Web of Science ®Google Scholar
• Steitz JA, Vasudevan S. miRNPs: versatile regulators of gene expression in vertebrate cells. Biochem. Soc. Trans.37(Pt 5), 931–935 (2009).
   PubMedGoogle Scholar
• Richter JD. Think you know how miRNAs work? Think again. Nat. Struct. Mol. Biol.15(4), 334–336 (2008).
   PubMedGoogle Scholar
• Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat. Rev. Genet.9(2), 102–114 (2008).
   PubMed Web of Science ®Google Scholar
• John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS. Human microRNA targets. PLoS Biol.2(11), e363 (2004).
   PubMed Web of Science ®Google Scholar
• Maragkakis M, Reczko M, Simossis VA et al. DIANA-microT web server: elucidating microRNA functions through target prediction. Nucleic Acids Res.37(Web Server issue), W273–W276 (2009).
   PubMed Web of Science ®Google Scholar
• Rehmsmeier M, Steffen P, Hochsmann M, Giegerich R. Fast and effective prediction of microRNA/target duplexes. RNA10(10), 1507–1517 (2004).
   PubMed Web of Science ®Google Scholar
• Rusinov V, Baev V, Minkov IN, Tabler M. MicroInspector: a web tool for detection of miRNA binding sites in an RNA sequence. Nucleic Acids Res.33(Web Server issue), W696–W700 (2005).
   PubMed Web of Science ®Google Scholar
• Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell120(1), 15–20 (2005).
   PubMed Web of Science ®Google Scholar
• Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell115(7), 787–798 (2003).
   PubMed Web of Science ®Google Scholar
• Li L, Xu J, Yang D, Tan X, Wang H. Computational approaches for microRNA studies: a review. Mamm. Genome21(1–2), 1–12 (2009).
   PubMedGoogle Scholar
• Rajewsky N. microRNA target predictions in animals. Nat. Genet.38(Suppl.), S8–S13 (2006).
   PubMed Web of Science ®Google Scholar
• Kertesz M, Iovino N, Unnerstall U, Gaul U, Segal E. The role of site accessibility in microRNA target recognition. Nat. Genet.39(10), 1278–1284 (2007).
   PubMed Web of Science ®Google Scholar
• Thadani R, Tammi MT. MicroTar: predicting microRNA targets from RNA duplexes. BMC Bioinform.7(Suppl. 5), S20 (2006).
   PubMedGoogle Scholar
• Miranda KC, Huynh T, Tay Y et al. A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. Cell126(6), 1203–1217 (2006).
   PubMed Web of Science ®Google Scholar
• Baek D, Villen J, Shin C, Camargo FD, Gygi SP, Bartel DP. The impact of microRNAs on protein output. Nature455(7209), 64–71 (2008).
   PubMed Web of Science ®Google Scholar
• Selbach M, Schwanhausser B, Thierfelder N et al. Widespread changes in protein synthesis induced by microRNAs. Nature455, 58–63 (2008).
   PubMed Web of Science ®Google Scholar
• Petrelli NJ, Winer EP, Brahmer J et al. Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening – a report from the American Society of Clinical Oncology. J. Clin. Oncol.27(35), 6052–6069 (2009).
   PubMed Web of Science ®Google Scholar
• Paranjape T, Slack FJ, Weidhaas JB. MicroRNAs: tools for cancer diagnostics. Gut58(11), 1546–1554 (2009).
   PubMed Web of Science ®Google Scholar
• Liu CG, Calin GA, Meloon B et al. An oligonucleotide microchip for genome-wide microRNA profiling in human and mouse tissues. Proc. Natl Acad. Sci. USA101(26), 9740–9744 (2004).
   PubMed Web of Science ®Google Scholar
• Esquela-Kerscher A, Slack FJ. Oncomirs – microRNAs with a role in cancer. Nat. Rev. Cancer6(4), 259–269 (2006).
   PubMed Web of Science ®Google Scholar
• Lu J, Getz G, Miska EA et al. MicroRNA expression profiles classify human cancers. Nature435(7043), 834–838 (2005).
   PubMed Web of Science ®Google Scholar
• Klein U, Lia M, Crespo M et al. The DLEU2/miR-15a/16–1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell17(1), 28–40 (2010).
   PubMed Web of Science ®Google Scholar
• Pharoah PD, Dunning AM, Ponder BA, Easton DF. Association studies for finding cancer-susceptibility genetic variants. Nat. Rev. Cancer4(11), 850–860 (2004).
   PubMed Web of Science ®Google Scholar
• Yu Z, Li Z, Jolicoeur N et al. Aberrant allele frequencies of the SNPs located in microRNA target sites are potentially associated with human cancers. Nucleic Acids Res.35(13), 4535–4541 (2007).
   PubMed Web of Science ®Google Scholar
• He H, Jazdzewski K, Li W et al. The role of microRNA genes in papillary thyroid carcinoma. Proc. Natl Acad. Sci. USA102(52), 19075–19080 (2005).
   PubMed Web of Science ®Google Scholar
• Melillo RM, Castellone MD, Guarino V et al. The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J. Clin. Invest.115(4), 1068–1081 (2005).
   PubMed Web of Science ®Google Scholar
• Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC–RAS–BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res.63(7), 1454–1457 (2003).
   PubMed Web of Science ®Google Scholar
• Nikiforova MN, Chiosea SI, Nikiforov YE. MicroRNA expression profiles in thyroid tumors. Endocr. Pathol.20(2), 85–91 (2009).
   PubMed Web of Science ®Google Scholar
• Felli N, Fontana L, Pelosi E et al. MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc. Natl Acad. Sci. USA102(50), 18081–18086 (2005).
   PubMed Web of Science ®Google Scholar
• Natali PG, Berlingieri MT, Nicotra MR et al. Transformation of thyroid epithelium is associated with loss of c-kit receptor. Cancer Res.55(8), 1787–1791 (1995).
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J. Clin.58(2), 71–96 (2008).
   PubMed Web of Science ®Google Scholar
• Robles-Diaz L, Goldfrank DJ, Kauff ND, Robson M, Offit K. Hereditary ovarian cancer in Ashkenazi Jews. Fam. Cancer3(3–4), 259–264 (2004).
   PubMedGoogle Scholar
• Wacholder S, Struewing JP, Hartge P, Greene MH, Tucker MA. Breast cancer risks for BRCA1/2 carriers. Science306(5705), 2187–2191; author reply 2187–2191 (2004).
   PubMedGoogle Scholar
• Kontorovich T, Levy A, Korostishevsky M, Nir U, Friedman E. SNPs in miRNA binding sites and miRNA genes as breast/ovarian cancer risk modifiers in Jewish high risk women. Int. J. Cancer(2009).
   Google Scholar
• Iorio MV, Ferracin M, Liu CG et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res.65(16), 7065–7070 (2005).
   Google Scholar
• Bartels CL, Tsongalis GJ. MicroRNAs: novel biomarkers for human cancer. Clin. Chem.55(4), 623–631 (2009).
   PubMed Web of Science ®Google Scholar
• Adams BD, Furneaux H, White BA. The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-α (ERα) and represses ERα messenger RNA and protein expression in breast cancer cell lines. Mol. Endocrinol.21(5), 1132–1147 (2007).
   PubMed Web of Science ®Google Scholar
• Brendle A, Lei H, Brandt A et al. Polymorphisms in predicted microRNA-binding sites in integrin genes and breast cancer: ITGB4 as prognostic marker. Carcinogenesis29(7), 1394–1399 (2008).
   PubMed Web of Science ®Google Scholar
• Dalmay T, Edwards DR. MicroRNAs and the hallmarks of cancer. Oncogene25(46), 6170–6175 (2006).
   PubMed Web of Science ®Google Scholar
• Tchatchou S, Jung A, Hemminki K et al. A variant affecting a putative miRNA target site in estrogen receptor (ESR) 1 is associated with breast cancer risk in premenopausal women. Carcinogenesis30(1), 59–64 (2009).
   PubMedGoogle Scholar
• Saetrom P, Biesinger J, Li SM et al. A risk variant in an miR-125b binding site in BMPR1B is associated with breast cancer pathogenesis. Cancer Res.69(18), 7459–7465 (2009).
   PubMed Web of Science ®Google Scholar
• Blenkiron C, Goldstein LD, Thorne NP et al. MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol.8(10), R214 (2007).
   PubMed Web of Science ®Google Scholar
• Mattie MD, Benz CC, Bowers J et al. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol. Cancer5, 24 (2006).
   PubMed Web of Science ®Google Scholar
• Song F, Zheng H, Liu B et al. An miR-502-binding site single-nucleotide polymorphism in the 3´-untranslated region of the SET8 gene is associated with early age of breast cancer onset. Clin. Cancer Res.15(19), 6292–6300 (2009).
   PubMedGoogle Scholar
• van Hest LP, Ruijs MW, Wagner A et al. Two TP53 germline mutations in a classical Li-Fraumeni syndrome family. Fam. Cancer6(3), 311–316 (2007).
   PubMedGoogle Scholar
• Tabori U, Nanda S, Druker H, Lees J, Malkin D. Younger age of cancer initiation is associated with shorter telomere length in Li-Fraumeni syndrome. Cancer Res.67(4), 1415–1418 (2007).
   PubMed Web of Science ®Google Scholar
• Pongsavee M, Yamkamon V, Dakeng S et al. The BRCA1 3´-UTR: 5711+421T/T_5711+1286T/T genotype is a possible breast and ovarian cancer risk factor. Genet. Test. Mol. Biomarkers13(3), 307–317 (2009).
   PubMed Web of Science ®Google Scholar
• Nicoloso MS, Sun H, Spizzo R et al. Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility. Cancer Res.70(7), 2789–2798 (2010).
   PubMed Web of Science ®Google Scholar
• Orom UA, Nielsen FC, Lund AH. MicroRNA-10a binds the 5´UTR of ribosomal protein mRNAs and enhances their translation. Mol. Cell30(4), 460–471 (2008).
   PubMed Web of Science ®Google Scholar
• Vasudevan S, Tong Y, Steitz JA. Switching from repression to activation: microRNAs can up-regulate translation. Science318(5858), 1931–1934 (2007).
   PubMed Web of Science ®Google Scholar
• Peto R. Influence of dose and duration of smoking on lung cancer rates. IARC Sci. Publ. (74), 23–33 (1986).
   PubMedGoogle Scholar
• Alberg AJ, Samet JM. Epidemiology of lung cancer. Chest123(Suppl. 1), 21S–49S (2003).
   PubMed Web of Science ®Google Scholar
• Johnson SM, Grosshans H, Shingara J et al. RAS is regulated by the let-7 microRNA family. Cell120(5), 635–647 (2005).
   PubMed Web of Science ®Google Scholar
• Calin GA, Sevignani C, Dumitru CD et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc. Natl Acad. Sci. USA101(9), 2999–3004 (2004).
   PubMed Web of Science ®Google Scholar
• Takamizawa J, Konishi H, Yanagisawa K et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res.64(11), 3753–3756 (2004).
   PubMed Web of Science ®Google Scholar
• Yanaihara N, Caplen N, Bowman E et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell9(3), 189–198 (2006).
   PubMed Web of Science ®Google Scholar
• Rodenhuis S, Slebos RJ. Clinical significance of ras oncogene activation in human lung cancer. Cancer Res.52(Suppl. 9), 2665S–2669S (1992).
   PubMed Web of Science ®Google Scholar
• Lea IA, Jackson MA, Li X, Bailey S, Peddada SD, Dunnick JK. Genetic pathways and mutation profiles of human cancers: site- and exposure-specific patterns. Carcinogenesis28(9), 1851–1858 (2007).
   PubMed Web of Science ®Google Scholar
• Hoa M, Davis SL, Ames SJ, Spanjaard RA. Amplification of wild-type K-ras promotes growth of head and neck squamous cell carcinoma. Cancer Res.62(24), 7154–7156 (2002).
   PubMed Web of Science ®Google Scholar
• Chin LJ, Ratner E, Leng S et al. A SNP in a let-7 microRNA complementary site in the KRAS 3´ untranslated region increases non-small cell lung cancer risk. Cancer Res.68(20), 8535–8540 (2008).
   PubMed Web of Science ®Google Scholar
• Nelson HH, Christiani DC, Mark EJ, Wiencke JK, Wain JC, Kelsey KT. Implications and prognostic value of K-ras mutation for early-stage lung cancer in women. J. Natl Cancer Inst.91(23), 2032–2038 (1999).
   PubMed Web of Science ®Google Scholar
• Nelson HH, Christensen BC, Plaza SL, Wiencke JK, Marsit CJ, Kelsey KT. KRAS mutation, KRAS-LCS6 polymorphism, and non-small cell lung cancer. Lung Cancer69(1), 51–53 (2009).
   PubMedGoogle Scholar
• Christensen BC, Moyer BJ, Avissar M et al. A let-7 microRNA-binding site polymorphism in the KRAS 3´ UTR is associated with reduced survival in oral cancers. Carcinogenesis30(6), 1003–1007 (2009).
   PubMed Web of Science ®Google Scholar
• Graziano F, Canestrari E, Loupakis F et al. Genetic modulation of the Let-7 microRNA binding to KRAS 3´-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan. Pharmacogenomics J. DOI:10.1038/tpj.2010.9. (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Liu X, Chen Z, Yu J, Xia J, Zhou X. MicroRNA profiling and head and neck cancer. Comp. Funct. Genomics837514 (2009).
   PubMedGoogle Scholar
• Jemal A, Murray T, Ward E et al. Cancer statistics, 2005. CA Cancer J. Clin.55(1), 10–30 (2005).
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J. Clin.59(4), 225–249 (2009).
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E et al. Cancer statistics, 2006. CA Cancer J. Clin.56(2), 106–130 (2006).
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J. Clin.57(1), 43–66 (2007).
   PubMed Web of Science ®Google Scholar
• Blot WJ, McLaughlin JK, Winn DM et al. Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res.48(11), 3282–3287 (1988).
   PubMed Web of Science ®Google Scholar
• Furniss CS, McClean MD, Smith JF et al. Human papillomavirus 16 and head and neck squamous cell carcinoma. Int. J. Cancer120(11), 2386–2392 (2007).
   PubMed Web of Science ®Google Scholar
• Ng SK, Kabat GC, Wynder EL. Oral cavity cancer in non-users of tobacco. J. Natl Cancer Inst.85(9), 743–745 (1993).
   PubMedGoogle Scholar
• Tran N, McLean T, Zhang X et al. MicroRNA expression profiles in head and neck cancer cell lines. Biochem. Biophys. Res. Commun.358(1), 12–17 (2007).
   PubMed Web of Science ®Google Scholar
• Chang SS, Jiang WW, Smith I et al. MicroRNA alterations in head and neck squamous cell carcinoma. Int. J. Cancer123(12), 2791–2797 (2008).
   PubMed Web of Science ®Google Scholar
• Ramdas L, Giri U, Ashorn CL et al. miRNA expression profiles in head and neck squamous cell carcinoma and adjacent normal tissue. Head Neck31(5), 642–654 (2009).
   PubMedGoogle Scholar
• Potter JD. Colorectal cancer: molecules and populations. J. Natl Cancer Inst.91(11), 916–932 (1999).
   PubMed Web of Science ®Google Scholar
• Aslam MI, Taylor K, Pringle JH, Jameson JS. MicroRNAs are novel biomarkers of colorectal cancer. Br. J. Surg.96(7), 702–710 (2009).
   PubMed Web of Science ®Google Scholar
• Xu Z, Taylor JA. SNPinfo: integrating GWAS and candidate gene information into functional SNP selection for genetic association studies. Nucleic Acids Res.37(Web Server issue), W600–W605 (2009).
   PubMed Web of Science ®Google Scholar
• Zhang W, Dahlberg JE, Tam W. MicroRNAs in tumorigenesis: a primer. Am. J. Pathol.171(3), 728–738 (2007).
   PubMed Web of Science ®Google Scholar
• Volinia S, Calin GA, Liu CG et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl Acad. Sci. USA103(7), 2257–2261 (2006).
   PubMed Web of Science ®Google Scholar
• Cummins JM, He Y, Leary RJ et al. The colorectal microRNAome. Proc. Natl Acad. Sci. USA103(10), 3687–3692 (2006).
   PubMed Web of Science ®Google Scholar
• Xi Y, Formentini A, Chien M et al. Prognostic values of microRNAs in colorectal cancer. Biomark. Insights2, 113–121 (2006).
   PubMedGoogle Scholar
• Asangani IA, Rasheed SA, Nikolova DA et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene27(15), 2128–2136 (2008).
   PubMed Web of Science ®Google Scholar
• Grady WM, Parkin RK, Mitchell PS et al. Epigenetic silencing of the intronic microRNA hsa-miR-342 and its host gene EVL in colorectal cancer. Oncogene27(27), 3880–3888 (2008).
   PubMed Web of Science ®Google Scholar
• Guo C, Sah JF, Beard L, Willson JK, Markowitz SD, Guda K. The noncoding RNA, miR-126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3-kinase signaling and is frequently lost in colon cancers. Genes Chromosomes Cancer47(11), 939–946 (2008).
   PubMed Web of Science ®Google Scholar
• Michael MZ, SM OC, van Holst Pellekaan NG, Young GP, James RJ. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol. Cancer Res.1(12), 882–891 (2003).
   PubMed Web of Science ®Google Scholar
• Tazawa H, Tsuchiya N, Izumiya M, Nakagama H. Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc. Natl Acad. Sci. USA104(39), 15472–15477 (2007).
   PubMed Web of Science ®Google Scholar
• Monzo M, Navarro A, Bandres E et al. Overlapping expression of microRNAs in human embryonic colon and colorectal cancer. Cell Res.18(8), 823–833 (2008).
   PubMed Web of Science ®Google Scholar
• Landi D, Gemignani F, Naccarati A et al. Polymorphisms within micro-RNA-binding sites and risk of sporadic colorectal cancer. Carcinogenesis29(3), 579–584 (2008).
   PubMed Web of Science ®Google Scholar
• Nguyen MH, Keeffe EB. Epidemiology and treatment outcomes of patients with chronic hepatitis C and genotypes 4 to 9. Rev. Gastroenterol Disord.4(Suppl. 1), S14–S21 (2004).
   PubMedGoogle Scholar
• Srivatanakul P, Sriplung H, Deerasamee S. Epidemiology of liver cancer: an overview. Asian Pac. J. Cancer Prev.5(2), 118–125 (2004).
   PubMedGoogle Scholar
• Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat. Genet.31(4), 339–346 (2002).
   PubMed Web of Science ®Google Scholar
• Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut54(4), 533–539 (2005).
   PubMed Web of Science ®Google Scholar
• Caldwell S, Park SH. The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology. J. Gastroenterol.44(Suppl. 19), 96–101 (2009).
   PubMedGoogle Scholar
• Chen S, He Y, Ding J et al. An insertion/deletion polymorphism in the 3´ untranslated region of β-transducin repeat-containing protein (βTrCP) is associated with susceptibility for hepatocellular carcinoma in Chinese. Biochem. Biophys. Res. Commun.391(1), 552–556 (2010).
   PubMedGoogle Scholar
• Murakami Y, Yasuda T, Saigo K et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene25(17), 2537–2545 (2006).
   PubMed Web of Science ®Google Scholar
• Jiang J, Gusev Y, Aderca I et al. Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin. Cancer Res.14(2), 419–427 (2008).
   PubMed Web of Science ®Google Scholar
• Gao Y, He Y, Ding J et al. An insertion/deletion polymorphism at miRNA-122-binding site in the interleukin-1α 3´ untranslated region confers risk for hepatocellular carcinoma. Carcinogenesis30(12), 2064–2069 (2009).
   PubMed Web of Science ®Google Scholar
• Apte RN, Voronov E. Is interleukin-1 a good or bad ‘guy’ in tumor immunobiology and immunotherapy? Immunol. Rev.222, 222–241 (2008).
   PubMed Web of Science ®Google Scholar
• Busino L, Donzelli M, Chiesa M et al. Degradation of Cdc25A by β-TrCP during S phase and in response to DNA damage. Nature426(6962), 87–91 (2003).
   PubMed Web of Science ®Google Scholar
• Ougolkov A, Zhang B, Yamashita K et al. Associations among β-TrCP, an E3 ubiquitin ligase receptor, β-catenin, and NF-κB in colorectal cancer. J. Natl Cancer Inst.96(15), 1161–1170 (2004).
   PubMed Web of Science ®Google Scholar
• Kudo Y, Guardavaccaro D, Santamaria PG et al. Role of F-box protein βTrcp1 in mammary gland development and tumorigenesis. Cell. Mol. Biol.24(18), 8184–8194 (2004).
   Google Scholar
• Koch A, Waha A, Hartmann W et al. Elevated expression of Wnt antagonists is a common event in hepatoblastomas. Clin. Cancer Res.11(12), 4295–4304 (2005).
   PubMed Web of Science ®Google Scholar